Cioffi W G, Burleson D G, Pruitt B A
US Army Institute of Surgical Research, Fort Sam Houston, Tex.
Arch Surg. 1993 Nov;128(11):1260-7. doi: 10.1001/archsurg.1993.01420230088014.
Injury elicits a response from all cells of the immune system in which cytokines and other metabolic products of activated leukocytes can act either beneficially to provide for enhanced host resistance or deleteriously to depress the function of remote organs and cause what has been termed systemic inflammation. These at times antithecal responses of leukocytes that appear to integrate postinjury changes in the neuroendocrine, immune, and coagulation systems have been implicated as principal causative factors in multiple systems organ failure. Numerous investigators have evaluated a variety of therapeutic agents to prevent and control infection by restoring leukocyte function, while others have evaluated antagonists and monoclonal antibodies as a means of controlling the exaggerated and persistent actions of leukocytes and cytokines caused by systemic inflammation. The redundancies of the cell populations and the cytokines and other metabolites produced by the cells predictably limit the effectiveness of any single agent and make clinical evaluation of such agents difficult.
损伤会引发免疫系统所有细胞的反应,其中细胞因子和活化白细胞的其他代谢产物既可以发挥有益作用,增强宿主抵抗力,也可能产生有害影响,抑制远处器官功能并导致所谓的全身炎症。白细胞的这些有时相互矛盾的反应似乎整合了损伤后神经内分泌、免疫和凝血系统的变化,被认为是多系统器官功能衰竭的主要致病因素。许多研究人员评估了多种治疗药物以通过恢复白细胞功能来预防和控制感染,而其他研究人员则评估了拮抗剂和单克隆抗体,作为控制全身炎症引起的白细胞和细胞因子过度且持续作用的手段。细胞群体以及细胞产生的细胞因子和其他代谢产物的冗余性,可预见地限制了任何单一药物的有效性,并使此类药物的临床评估变得困难。